<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187966</url>
  </required_header>
  <id_info>
    <org_study_id>NW-1015/016/III/2006</org_study_id>
    <nct_id>NCT01187966</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease</brief_title>
  <official_title>A Phase III, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Patients With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, and/or an Anticholinergic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newron Pharmaceuticals SPA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newron Pharmaceuticals SPA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide&#xD;
      (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic&#xD;
      Parkinson's disease with motor fluctuations who are currently receiving a stable dose of&#xD;
      levodopa.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in mean daily &quot;on&quot; time</measure>
    <time_frame>baseline to endpoint</time_frame>
    <description>Increase in mean daily &quot;on&quot; time (&quot;on&quot; time without dyskinesia plus &quot;on&quot; time with minor dyskinesia) during 18-hr diary recording period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in total daily &quot;off&quot; time</measure>
    <time_frame>baseline to endpoint</time_frame>
    <description>Decrease in total daily &quot;off&quot; time, UPDRS Section III during &quot;on&quot; phase (based on diary) - mean change from baseline to endpoint, CGI - Change from baseline - mean score in the course of the study, change in cognition (cognitive test battery), decrease in mean &quot;off&quot; time following first morning dose of levodopa, improvement in the Dyskinesias Rating Scale during &quot;on&quot; phase, UPDRS Section II during &quot;on&quot; phase (based on diary),CGI- Severity of illness - mean change from baseline to endpoint, mean percent change in levodopa dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">669</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose (100mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose (50mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide</intervention_name>
    <arm_group_label>Low dose (50mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Safinamide</intervention_name>
    <arm_group_label>High Dose (100mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients are male or female, age 30-80 years, inclusive. If female, they must be&#xD;
             either post-menopausal for at least 12 months, surgically sterilized or have undergone&#xD;
             hysterectomy. Patients older than 80 years, who meet all other entry criteria, will be&#xD;
             considered for enrollment, with approval of the Newron Medical Expert.&#xD;
&#xD;
          -  Patients must have a diagnosis of idiopathic Parkinson's disease of more than 5 years&#xD;
             duration; the diagnosis should be based on medical history and neurological&#xD;
             examination. Patients with a duration of Parkinson's disease of at least 3 years, who&#xD;
             meet all other entry criteria, will be considered for enrollment, with approval of the&#xD;
             CRO Medical Monitor.&#xD;
&#xD;
          -  Patients must have a Hoehn and Yahr stage of I-IV during an &quot;off&quot; phase.&#xD;
&#xD;
          -  Patients should be levodopa responsive and must have been receiving treatment with a&#xD;
             stable dose of levodopa [4-10 doses per day of any levodopa preparation (including CR,&#xD;
             IR or a combination of CR/IR), plus benserazide/carbidopa; with or without addition of&#xD;
             a COMT inhibitor] and may be receiving concomitant treatment with stable doses of a&#xD;
             dopamine agonist and/or an anticholinergic at the screening visit. Patients will&#xD;
             receive the study medication as add-on therapy starting at baseline.&#xD;
&#xD;
          -  Patients should have motor fluctuations, with &gt;1.5 hours &quot;off&quot; time during the day.&#xD;
&#xD;
          -  Patients must be able to maintain an accurate and complete diary (18-hour), with the&#xD;
             help of a caregiver, recording &quot;on&quot; time, &quot;on&quot; time with minor dyskinesia, &quot;on&quot; time&#xD;
             with troublesome dyskinesia, &quot;off&quot; time, and time asleep.&#xD;
&#xD;
          -  Patients must be able to understand and willing to sign an approved Informed Consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The patient has any indication of forms of parkinsonism other than idiopathic&#xD;
             Parkinson's disease.&#xD;
&#xD;
          -  If female, the patient is of childbearing potential, pregnant or lactating.&#xD;
&#xD;
          -  The patient is in a late stage of Parkinson's disease, and is experiencing severe,&#xD;
             disabling peak-dose or biphasic dyskinesia and/or unpredictable or widely swinging&#xD;
             fluctuations in their symptoms.&#xD;
&#xD;
          -  The patient has a current diagnosis of substance abuse (DSM-IV) or history of alcohol&#xD;
             or drug abuse in the past 3 months.&#xD;
&#xD;
          -  The patient has a current clinically significant gastrointestinal, renal, hepatic,&#xD;
             endocrine, pulmonary or cardiovascular disease, including acute gastric ulcer,&#xD;
             hypertension that is not well-controlled, asthma, chronic obstructive pulmonary&#xD;
             disease (COPD), and Type I diabetes. Patients with a history of gastric ulcer who have&#xD;
             not had an episode of acute gastritis in the last 6 months and are not currently&#xD;
             experiencing gastric pain will be eligible for inclusion.&#xD;
&#xD;
          -  The patient has second- or third-degree atrio-ventricular block or sick sinus&#xD;
             syndrome, uncontrolled atrial fibrillation, severe or unstable angina, congestive&#xD;
             heart failure, myocardial infarction within 3 months of the screening visit, or a&#xD;
             significant ECG abnormality, including QTc ≥ 450 msec (males) or ≥ 470 msec (females),&#xD;
             where QTc is based on Bazett's correction method.&#xD;
&#xD;
          -  The patient has participated in a previous clinical trial with safinamide.&#xD;
&#xD;
          -  The patient has a concomitant disease likely to interfere with the study medication&#xD;
             (e.g. capable of altering absorption, metabolism or elimination of the study drug).&#xD;
&#xD;
          -  The patient has a history of psychosis (e.g. schizophrenia or psychotic depression),&#xD;
             either previously or currently, or a score ≥ 3 on Item 2 (thought disorder) or 3&#xD;
             (depression) of the UPDRS Section I.&#xD;
&#xD;
          -  The patient has evidence of dementia or cognitive dysfunction, as indicated by a MMSE&#xD;
             score &lt; 22, or a score ≥ 3 on item 1 (mentation) of the UPDRS, Section I.&#xD;
&#xD;
          -  The patient is depressed, as indicated by a GRID-HAMD (17-item scale) score &gt; 17.&#xD;
&#xD;
          -  The patient has a history of allergic response to anticonvulsants, levodopa, or other&#xD;
             anti-parkinsonian agents.&#xD;
&#xD;
          -  The patient has a mental or physical condition (e.g., neurotic behaviour, crippling&#xD;
             degenerative arthritis, or limb amputation), which would preclude performing efficacy&#xD;
             or safety assessments.&#xD;
&#xD;
          -  The patient has hypersenstivity or contraindications to MAO B inhibitors.&#xD;
&#xD;
          -  The patient has a current history of severe dizziness or fainting on standing, due to&#xD;
             postural hypotension.&#xD;
&#xD;
          -  The patient has a neoplastic disorder, which is either currently active or has been in&#xD;
             remission for less than one year.&#xD;
&#xD;
          -  The patient has had stereotactic surgery as a treatment for his/her Parkinson's&#xD;
             disease.&#xD;
&#xD;
          -  The patient has participated in a previous clinical trial within 30 days of entry into&#xD;
             the study (screening visit) or has received treatment with any investigational&#xD;
             compound within 30 days or 5 half-lives, whichever is longer, prior to screening. The&#xD;
             use of an investigational drug other than safinamide during the study is not&#xD;
             permitted.&#xD;
&#xD;
          -  The patient is receiving treatment of his/her depression with a MAO inhibitor (e.g.,&#xD;
             selegiline), a tricyclic, or an SNRI (e.g., venlafaxine, duloxetine) at the screening&#xD;
             visit. Note: Use of SSRIs will be permitted, provided the dose is kept as low as&#xD;
             possible and remains stable throughout the trial.&#xD;
&#xD;
          -  The patient is receiving treatment of his/her parkinsonian symptoms with a MAO&#xD;
             inhibitor. Note: Patients receiving amantadine, COMT inhibitors, DA agonists and/or&#xD;
             anticholinergics will be eligible to enter the trial, provided they are on a stable&#xD;
             dose at screening.&#xD;
&#xD;
          -  The patient has received treatment with any agent known to significantly inhibit or&#xD;
             induce drug-metabolizing enyzmes (e.g., barbiturates, phenothiazines, etc.) within 4&#xD;
             weeks preceding the screening visit.&#xD;
&#xD;
          -  The patient has received treatment with opioids (e.g., tramadol, meperidine&#xD;
             derivatives), in the 4 weeks prior to the screening visit.&#xD;
&#xD;
          -  The patient has received treatment with a depot neuroleptic within one injection&#xD;
             cycle, or oral neuroleptics within 4 weeks prior to the screening visit. Patients who&#xD;
             are receiving a low dose of an oral neuroleptic for treatment of psychotic symptoms&#xD;
             (e.g., hallucinations) related to their Parkinson's disease or anti-parkinsonian&#xD;
             medication, and who meet all other entry criteria, will be considered for enrollment,&#xD;
             with approval of the CRO Medical Monitor. The Investigator must agree not to increase&#xD;
             the dose of the oral neuroleptic during the trial, unless required for significant&#xD;
             worsening.&#xD;
&#xD;
          -  The patient has received treatment with a drug that has hepatotoxic potential, e.g.,&#xD;
             tamoxifen, within 4 weeks, or received radiation therapy or a drug with cytotoxic&#xD;
             potential, e.g, chemotherapy, within one year prior to the screening visit.&#xD;
&#xD;
          -  The patient has a history or a current diagnosis of HIV, tests positive for Hepatitis&#xD;
             B surface antigen, tests positive for Hepatitis B core antibody, but negative for&#xD;
             Hepatitis B surface antibody, or tests positive for Hepatitis C antibodies.&#xD;
&#xD;
          -  The patient has any abnormality that the investigator deems to be clinically relevant,&#xD;
             either on medical history, physical examination, ECG or a diagnostic laboratory test.&#xD;
&#xD;
          -  In the judgment of the Clinical Investigator the patient is likely to be non-compliant&#xD;
             or uncooperative during the study.&#xD;
&#xD;
          -  Ophthalmologic history including any of the following conditions: albino patients,&#xD;
             family history of hereditary retinal disease, progressive and/or severe diminution of&#xD;
             visual acuity (i.e., 20/70), retinitis pigmentosa, retinal pigmentation due to any&#xD;
             cause, any active retinopathy or ocular inflammation (uveitis), or progressive, severe&#xD;
             diabetic retinopathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohit Bhatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jaslok Hospital, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neeta Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J.J Hospital, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sankhla Charulata, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>P.D. Hinduja Hospital, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajit Sowani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Centre, Ahmedabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prosenjit Chakraborty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roby General Hospital, Kolkata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sudhir Kothari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Poona Hospital, Pune</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunil Bandishti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruby Hall Clinic, Pune</affiliation>
  </overall_official>
  <overall_official>
    <last_name>CU Velmurugendran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Ramachandra Medical College, Chennai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suresh Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vijaya Health Centre, Chennai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Devanathan Vasudevan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kamakshi Memorial Hospital, Chennai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rupam Borgohain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nizams Institute of Medical Sciences, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J.K Murthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CARE Hospital, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vavilikolanu Prasad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Owasis Hospital &amp; Research Centre, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Subashini Prabhakar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spectra Clinical Research Centre, Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keshava Belur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>J.S.S. Hospital Agrahara, Mysore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pramod Pal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NIMHANS, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ajit Kumar Roy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Johns Medical College and Hospital, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rangashetti Srinivasa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S. Ramaiah Memoria Hospital, Bangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arun B Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>T.N.M.C and B.Y.L Nair Hospital, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Krishnan Vijayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kovai Medical Centre and Hospital, Coimbatore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neeta Mehta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neeta Mehta's Clinic, Mumbai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chandrashekhar Meshram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brain and Mind Institute, Nagpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nellikunja Shankar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mallikatta Neuro and Research Centre, Mangalore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asha Kishore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sree Chitra Tirual Institute for Sciences and Technology, Kerela</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ummer Karadan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baby Memorial Hospital, Calicut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammad I Sahadulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kerala Institute of Medical Sciences, Trivandrum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madhuri Behari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prahlad K Sethi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sir Ganga Ram Hospital, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shamsher Dwivedee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vidyasagar Institute of Mental Health and Neurosciences, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mukul Varma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indraprastha Apollo Hospital, New Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajinder Bansal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dayanand Medical College and Hospital, Ludhiana</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sudesh Prabhakar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Post Grad Institute of Medical Education,&amp; Research Dept of Neurology, Chandigarh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sunil Pradhan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Human Behaviour and Allied Sciences, Dilshad Garden Delhi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rakesh Shukla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chhatrapati Sahuji Maharaj Medical University, Lucknow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pahari Ghosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Aurbindo Seva Kendra, Kolkata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ovidiu Bajenaru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Emergency Hospital, Bucuresti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristina Panea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elias University Hospital, Bucuresti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Campeanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundeni Hospital, Bucuresti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Ticmeanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>colentina Hospital, Bucuresti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dafin Muresanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Hospital Cluj, Cluj</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelo Bulboaca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rehabilitation Hospital Cluj, Cluj</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jozsef Szasz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Hospital Targu-Mures, Targu Mures</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cristian Dinu Popescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rehabiliation Hospital Iasi, Iasi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mihaela Simu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Hospital Timisoara no. 1, Timisoara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Chirileanu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emergency Hospital Timisoara no.1, Timisoara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Eleopra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale dell'Angelo, Venezia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rocco Quatrale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arcispedale S. Anna, Ferrara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marco Onofri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro dell'invecchiamento, Chieti</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanina Pia Avarello, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro di Riferimento Regionale Malattie Extra Piramidali, Palermo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ubaldo Bonuccelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Viareggio, Viareggio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Fabbrini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dip. Scienze Neurologiche, Roma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo Stanzione, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome Tor Vergata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrizio Stocchi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS S. Raffaele Pisana, Roma</affiliation>
  </overall_official>
  <link>
    <url>http://www.newron.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>May 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Ravi Anand CMO</name_title>
    <organization>Newron Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>PD</keyword>
  <keyword>Levodopa</keyword>
  <keyword>Patients with idiopathic Parkinson's disease with motor fluctuations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 24, 2016</submitted>
    <returned>July 1, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

